We applied in silico and in vitro analyses to characterise a novel risk association between deletions overlapping SULT1A1 (OMIM 171150) and decreased breast cancer risk for BRCA1 pathogenic variant carriers. This evidence concerns the gene BRCA1 and breast cancer.